… efficacy of dapagliflozin on total HF events, ie, … cardiovascular deaths, in the population
with HFmrEF or HFpEF enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients …

… B, The median (IQR) follow-up times were the same in each group for the worsening heart
failure event … Dapagliflozin in patients with heart failure and reduced ejection fraction.  …

… the effects of dapagliflozin on major adverse cardiac events and … Serious adverse events
occurred more frequently in patients … of dapagliflozin versus placebo did not differ, with no effect …

… The effect of dapagliflozin vs placebo is presented as a rate ratio (95% CI) for the recurrent
event process and as a HR (95% CI) for the failure process. Safety data are reported by …

… Consistent with recent studies, this analysis showed no significant difference between
dapagliflozin and placebo in volume depletion events [25, 26]. Interestingly, the vast majority of …

… Because of the small number of renal events overall, this … event, adverse events leading to
discontinuation of trial treatment, adverse events of interest (ie volume depletion, renal events, …

… composite endpoint of cardiovascular death or a worsening HF event. Most randomized … ,
we compared the effect of dapagliflozin with placebo in subgroups of patients treated with other …

… the line of null effect. A and B are the results for the primary composite outcome of time to
first worsening heart failure event (a hospitalization or unplanned urgent heart visit requiring …

… of dapagliflozin 10 mg, compared with placebo, given once … heart failure event (hospitalization
or equivalent event, ie an … first as well as subsequent) heart failure events, again better …

… of major adverse cardiovascular events, defined as CV death… study the effect of dapagliflozin
on patients with heart failure, … mortality, cardiovascular mortality, and heart failure-related …